Trending...
- Red5 Taps PubNub to Power the Next Era of Real-Time Interactive Streaming
- NYC Composer/Educator Launches Debut Children's Book to Fantastic Reviews
- Vanguard Gifted Academy Students Join Millions Globally for World Maths Day 2026
SEOUL, South Korea, June 10, 2024 ~ During the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, J INTS BIO provided an update on their Phase 1 clinical study of JIN-A02, a 4th generation EGFR-TKI for the treatment of non-small cell lung cancer (NSCLC). The update was presented during the poster session on June 3rd.
The study, which began in May 2024 and is ongoing, aims to evaluate the safety and efficacy of JIN-A02 in patients with NSCLC. Professor Cho Byoung Chul, a leading researcher in the field of oncology, presented the update and posed with the JIN-A02 poster at the conference.
The latest update reported a partial response (PR) in a patient from Cohort 4 who received a daily dose of 100mg. This is the second PR recorded in the study, with the first being from a patient in an earlier cohort who received a lower dose of 50mg daily. Additionally, this is also the first instance of brain tumor activity being observed in Cohort 4, with a reduction of brain metastasis by 28.6%.
More on illi News
So far, two patients have shown partial response and three others have stable disease. This includes the patient from Cohort 4 with reduced brain metastasis and two patients from lower cohorts who received lower doses.
The final patient in Cohort 4 is expected to complete their dose-limiting toxicity (DLT) assessment soon and no DLT has been detected thus far. Furthermore, there have been no reports of common side effects such as rash, diarrhea or cardiac toxicity associated with EGFR TKIs use.
J INTS BIO expressed their excitement about sharing these key clinical results at such a prestigious conference attended by global anticancer experts and research and development officials. They also stated that JIN-A02 has potential to be a game changer in improving the lives of patients with EGFR C797S positive NSCLC, for which there is currently no approved treatment. The company plans to enter phase 2 clinical trials by the end of this year.
The next cohort, which will receive a daily dose of 150mg, is set to begin at the end of June. J INTS BIO believes that these results will pave the way for further advancements in the treatment of NSCLC and bring hope to patients and their families.
The study, which began in May 2024 and is ongoing, aims to evaluate the safety and efficacy of JIN-A02 in patients with NSCLC. Professor Cho Byoung Chul, a leading researcher in the field of oncology, presented the update and posed with the JIN-A02 poster at the conference.
The latest update reported a partial response (PR) in a patient from Cohort 4 who received a daily dose of 100mg. This is the second PR recorded in the study, with the first being from a patient in an earlier cohort who received a lower dose of 50mg daily. Additionally, this is also the first instance of brain tumor activity being observed in Cohort 4, with a reduction of brain metastasis by 28.6%.
More on illi News
- Mayor Brandon Johnson, DFSS, My Chi. My Future., Host Fifth Annual Teen Bash at Navy Pier, Empowering Young Chicagoans
- The City of Naperville Launches 2026 National Community Survey
- NRx Pharmaceuticals Could Be on the Verge of a Breakout Year as AI, FDA Catalysts, and Mental Health Demand Converge
- DC Accounting Firm Offers Free Business CRM to Small Business Clients Alongside Weekly Bookkeeping Model
- CCHR: Psychiatric Drugs Fuel Rising Death Toll: National Adverse Drug Event Awareness Day Confronts America's Medication Crisis
So far, two patients have shown partial response and three others have stable disease. This includes the patient from Cohort 4 with reduced brain metastasis and two patients from lower cohorts who received lower doses.
The final patient in Cohort 4 is expected to complete their dose-limiting toxicity (DLT) assessment soon and no DLT has been detected thus far. Furthermore, there have been no reports of common side effects such as rash, diarrhea or cardiac toxicity associated with EGFR TKIs use.
J INTS BIO expressed their excitement about sharing these key clinical results at such a prestigious conference attended by global anticancer experts and research and development officials. They also stated that JIN-A02 has potential to be a game changer in improving the lives of patients with EGFR C797S positive NSCLC, for which there is currently no approved treatment. The company plans to enter phase 2 clinical trials by the end of this year.
The next cohort, which will receive a daily dose of 150mg, is set to begin at the end of June. J INTS BIO believes that these results will pave the way for further advancements in the treatment of NSCLC and bring hope to patients and their families.
Filed Under: Business
0 Comments
Latest on illi News
- SelfCare is now HealthCare across America
- How a Former Fast Food Joint Became Peoria's Favorite Taproom - The Story behind Bust'd Brewing
- Isringhausen Team Member Recognized at 2026 DSI Awards
- Homeowner Prep Announces Strategic Language Shift: Replacing "Renters" with "Future Homeowners" to Inspire Wealth-Building Mindsets
- LiposoMore™ Redefines Bioavailability: Joyful Nutritional Launches High-Performance Liposomal Vitamin C and Iron for the Global Supplement Market
- GDE Tree Services Expands Operations into Sydney, NSW
- Tuckwell Machinery Expands CNC Range to Support Australian Cabinet Makers
- The Inner Power of Emotional Self-Leadership
- Dr. Nadene Rose Shares the Secret to True Success: Faith, Obedience, and Divine Purpose
- Understanding Unexpected Death: Why Independent Autopsies Matter in Cases Without Clear Cause
- Epic Pictures Group Sets North American Release Date for the Thriller NO ORDINARY HEIST
- Award-Winning REALTOR® Paige Coker Joins Corcoran DeRonja Real Estate
- Over 98% of crypto owners globally don't declare taxes, new report find
- Chicago: Mayor Brandon Johnson and BACP Announce Selected Organizations for the Neighborhood Retail Activation Program
- TicTac Group acquires French EdTech company Distrisoft
- Suburban Orthopaedics Expands Comprehensive Orthopaedic Care in Northwest Suburbs
- Chicago: Mayor Brandon Johnson Joins Goodman Theatre To Celebrate Opening of Theater of The Mind
- Chicago: Mayor Brandon Johnson Statement on Preliminary Ruling Restoring Red Line Extension Funding
- Kettera Strategies Selects Bite Stream
- Mark Dobosz Makes Donorassess.org Free To Every Nonprofit On The Planet